Clinical trials: Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease
Mild Cognitive Impairment (MCI), Mild Cognitive Impairment (MCI) Amnestic
Deep Brain Stimulation Guided by Brain Mapping to Treat Cognitive Impairment
This trial is a 12-month safety and feasibility study, enrolling up to six participants. These participants will serve as their own controls, structured in multiple parts that follow an initial short-term stereo…
- Conditions
- Mild Cognitive Impairment (MCI), Mild Cognitive Impairment (MCI) Amnestic, Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease, Memory Deficit
- Trial name
- NCT07887737
- Testing
- Abbott St Jude Medical Infinity™
- Volunteers
- 6 people
- Sponsor
- University of Texas Southwestern Medical Center
Alzheimer's Disease (AD), Mild Cognitive Impairment (MCI)
CMN LIFU for Enhanced Glymphatic Clearance in Amyloid-Positive MCI
The goal of this clinical trial is to learn if a wearable ultrasound device, called ATTN201, is safe and easy to use. The study is for adults ages 65 and older who have mild cognitive impairment (MCI) and a buildup of a protein…
- Conditions
- Alzheimer's Disease (AD), Mild Cognitive Impairment (MCI), Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease
- Trial name
- NCT07866768
- Testing
- ATTN201 Focused Ultrasound to the CMN, ATTN201 Unfocused Ultrasound
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of California, San Francisco
Alzheimer s Disease, Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease
NON-INVASIVE BRAIN STIMULATION FOR MEMORY LOSS IN EARLY ALZHEIMER'S DISEASE
The goal of this clinical trial is to learn if repetitive transcranial magnetic stimulation (rTMS), a non-invasive form of brain stimulation, can improve short-term memory in people with early Alzheimer's disease (AD).
- Conditions
- Alzheimer s Disease, Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease, Mild Dementia
- Trial name
- NCT07667478
- Testing
- repetitive transcranial magnetic stimulation (rTMS)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Chi-Ying (Roy) Lin
Subjective Cognitive Decline (SCD), Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease
Longitudinal Profiling of Plasma-Derived Glial Extracellular Vesicles in Alzheimer's Disease
This project aims to longitudinally profile plasma-derived GDEVs and plasma biomarkers of neuroinflammation across three stages of the AD continuum (Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's…
- Conditions
- Subjective Cognitive Decline (SCD), Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease, Alzheimer's Disease Dementia, Alzheimer's Disease (AD)
- Trial name
- GLEVAD (NCT07803055)
- Testing
- blood sampling
- Where
- Italy
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
PARKINSON DISEASE (Disorder), Parkinson
The Role of METhanogens in the PROgression Of Parkinson's Disease and Related Neurological Conditions
Gut problems, such as constipation, can have an important impact on quality of life of people who have them, and have been associated with higher risk of developing neurological diseases such as Parkinson's or Alzheimer's…
- Conditions
- PARKINSON DISEASE (Disorder), Parkinson, Parkinson Disease, Parkinson s Disease
- Trial name
- Met-Pro (NCT07786116)
- Testing
- Probiotic Supplementation with L. reuteri
- Where
- United Kingdom
- Volunteers
- 215 people, healthy volunteers welcome
- Sponsor
- University of Cambridge
Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease, Alzheimer's Disease
Safety Assessment of Leronlimab and Its Effect on Brain Inflammation in Alzheimer's Disease
The present study will administer the drug leronlimab to 20 participants who are above 50 years old with Alzheimer's disease (AD) or mild cognitive impairment (MCI) due to AD.
- Trial name
- SALIENT-AD (NCT07553338)
- Testing
- Leronlimab (700mg)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Weill Medical College of Cornell University
Alzheimer Disease, Anxiety
Cannabidiol Solution for the Treatment of Behavioral Symptoms in Older Adults With Mild Cognitive Impairment or Alzheimer's Dementia
This is an open label, eight week, clinical trial of a proprietary high CBD/low THC sublingual solution for the treatment of clinically significant anxiety and agitation in individuals with mild cognitive impairment (MCI) or mild…
- Conditions
- Alzheimer Disease, Anxiety, Agitation,Psychomotor, Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease
- Trial name
- CBD (NCT04075435)
- Testing
- high CBD/low THC sublingual solution
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Mclean Hospital
Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease
Infrared Light for Memory Loss in Mild Cognitive Impairment (MCI)
Mild cognitive impairment (MCI) is a transitional risk state that occurs between the normal aging process and Alzheimer's dementia (AD).
- Trial name
- PBMCI-Prime (NCT06618807)
- Testing
- Active tPBM device
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- Unity Health Toronto
Mild Cognitive Impairment (MCI), Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease
Mindfulness for Cognition in Early-stage Alzheimer's Disease
The goal of this clinical trial is to learn if mindfulness meditation can improve outcomes in older adults with and without cognitive impairment. The main questions it aims to answer are: 1.
- Conditions
- Mild Cognitive Impairment (MCI), Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease, TBI (Traumatic Brain Injury), Aging
- Trial name
- NCT06792877
- Testing
- Mindfulness Intervention, Waitlist then mindfulness
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- VA Boston Healthcare System
Mild Alzheimer's Disease, Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease
Medicare Anti-Aβ mAb Coverage With Evidence Development (CED) Study
The Anti-Aβ mAb CED Study is a prospective, longitudinal coverage with evidence development (CED) study using clinical data, patient assessments, and administrative claims data of the Medicare population, conducted in accordance…
- Trial name
- NCT06058234
- Testing
- Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease
- Where
- United States
- Volunteers
- 8,680 people
- Sponsor
- Centers for Medicare and Medicaid Services/ Coverage and Analysis Group